




OPEN

# Author Correction: Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer

Sara Moufarrij, Anil Srivastava, Stephanie Gomez, Melissa Hadley, Erica Palmer, Paul Tran Austin , Sarah Chisholm, Noor Diab, Kyle Roche, Angela Yu, Jing Li, Wenge Zhu, Micael Lopez-Acevedo, Alejandro Villagra & Katherine B. Chiappinelli

Correction to: *Scientific reports* <https://doi.org/10.1038/s41598-020-60409-4>, published online 26 February 2020

Noor Diab was omitted from the author list in the original version of this Article.

The Author Contributions section now reads:

S.M., A.S., M.L.-A., A.V., and K.B.C. designed the experiments. S.M., A.S., S.G., M.H., P.T.A., S.C., E.P., K.R., N.D., and A.Y. performed experiments. J.L. and W.Z. provided cisplatin-resistant cell lines IGROV-1 CR and SKOV3 CR. S.M., A.S., S.G., A.V., and K.B.C. wrote, edited, and revised the manuscript.

The original Article and accompanying Supplementary Information file has been corrected.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021

Published online: 20 December 2021